Serum free light chains in myeloma patients with an intact M protein by immunofixation: Potential roles for response assessment and prognosis during induction therapy with novel agents

Hematological Oncology

Volumn 30, Issue 3, 2012, Pages 156-162

  Mori, Sherry ^a   Crawford, Brooke S ^a   Roddy, Julianna V F ^a   Phillips, Gary ^a   Elder, Pat ^a   Hofmeister, Craig C ^a   Efebera, Yvonne ^a   Benson, Don M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Biomarker; Multiple myeloma; Serum free light chains

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BORTEZOMIB; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; M PROTEIN; THALIDOMIDE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; STEM CELL MOBILIZATION; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COMBINED MODALITY THERAPY; DEXAMETHASONE; DRUG MONITORING; DRUGS, INVESTIGATIONAL; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOGLOBULIN M; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; NEOPLASM, RESIDUAL; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRAZINES; REMISSION INDUCTION; THALIDOMIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 84866282542     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.1019     Document Type: Article

References (23)

1. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36(3): 842-854.
2. Nathans D, Fahey JL, Potter M. The formation of myeloma protein by mouse plasma cell tumor. J Exp Med 1958; 108(1): 121-130.
3. Salmon SE, Smith B. Immunoglobulin synthesis and total body tumor cell number in multiple IgG myeloma. J Clin Invest 1970; 49: 1114-1121.
4. Sullivan PW, Salmon SE. Kinetics of tumor growth and regression in IgG multiple myeloma. J Clin Invest 1970; 49(6): 1114-1121.
5. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47(4): 673-680.
6. Bradwell AR. Serum free light chain measurements move to center stage. Clin Chem 2005; 51(5): 805-807.
7. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23(2): 215-224.
8. Martin W, Abraham R, Shanafelt T, et al. Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Trans Res 2007; 149(4): 231-235.
9. Dispenzieri A, Zhang L, Katzmann JA, et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood 2008; 111(10): 4908-4915.
10. Benson DM, Panzner K, Hamadani M, et al. Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. Leuk Lymphoma 2010; 51(2): 243-251.
11. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. Br J Haematol 1998; 102(5): 1115-1123.
12. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58(2): 71-96.
13. Catley L, Anderson K. Strategies to improve the outcome of stem cell transplantation in multiple myeloma. Hematol J 2004; 5(1): 9-23.
14. Abraham RS, Clark RJ, Bryant SC, et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem 2002; 48(9): 655-657.
15. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006; 132(4): 410-451.
16. Fulton RB, Fernando SL. Serum free light chain assay reduces the need for serum and urine immunofixation electrophoresis in the evaluation of monoclonal gammopathy. Ann Clin Biochem 2009; 46(Pt 5): 407-412.
17. Giarin MM, Giaccone L, Sorasio R, et al. Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. Clin Chem 2009; 55(8): 1510-1516.
18. Siegel DS, McBride L, Bilotti E, et al. Inaccuracies in 24-hour urine testing for monoclonal gammopathies: serum free light chain analysis provides a more accurate measure of light chain burden than urine protein electrophoreses. Lab Med 2009; 40(6): 341-344.
19. Singhal S, Stein R, Vickrey E, Mehta J. The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias. Blood 2007; 109(8): 3611-3612.
20. Palumbo A, Rajkumar V. Multiple myeloma: chemotherapy or transplantation in the era of new drugs. Eur J Haematol 2010; 84(5): 379-390.
21. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010; 28(20): 4621-4629.
22. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008; 93(1): 124-127.
23. Giarin MM, Giaccone L, Sorasio R, et al. Serum free light chain ratio, total kappa/lambda ratio and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. Clin Chem 2009; 55(8): 1510-1516.